nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCB1—colon cancer	0.355	1	CbGaD
Canagliflozin—UGT1A9—Irinotecan—colon cancer	0.146	0.283	CbGbCtD
Canagliflozin—ABCC2—Irinotecan—colon cancer	0.0725	0.141	CbGbCtD
Canagliflozin—ABCC2—Vincristine—colon cancer	0.0634	0.123	CbGbCtD
Canagliflozin—ALB—Irinotecan—colon cancer	0.0452	0.0876	CbGbCtD
Canagliflozin—ALB—Fluorouracil—colon cancer	0.0434	0.0841	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—colon cancer	0.0384	0.0744	CbGbCtD
Canagliflozin—ALB—Methotrexate—colon cancer	0.0239	0.0464	CbGbCtD
Canagliflozin—ABCB1—Irinotecan—colon cancer	0.0236	0.0458	CbGbCtD
Canagliflozin—ABCB1—Vincristine—colon cancer	0.0207	0.0401	CbGbCtD
Canagliflozin—CYP3A4—Irinotecan—colon cancer	0.0142	0.0275	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—colon cancer	0.0125	0.0243	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—colon cancer	0.0124	0.024	CbGbCtD
Canagliflozin—ORM1—bile—colon cancer	0.00985	0.148	CbGeAlD
Canagliflozin—ABCC2—bile—colon cancer	0.0081	0.121	CbGeAlD
Canagliflozin—SLC5A2—renal system—colon cancer	0.00523	0.0784	CbGeAlD
Canagliflozin—SLC5A1—epithelium—colon cancer	0.00427	0.0641	CbGeAlD
Canagliflozin—SLC5A1—renal system—colon cancer	0.00396	0.0594	CbGeAlD
Canagliflozin—SLC5A2—vagina—colon cancer	0.00379	0.0568	CbGeAlD
Canagliflozin—SLC5A1—digestive system—colon cancer	0.00325	0.0487	CbGeAlD
Canagliflozin—SLC5A1—vagina—colon cancer	0.00287	0.043	CbGeAlD
Canagliflozin—ORM1—gall bladder—colon cancer	0.00274	0.041	CbGeAlD
Canagliflozin—UGT1A9—renal system—colon cancer	0.00249	0.0374	CbGeAlD
Canagliflozin—Hypovolaemia—Irinotecan—colon cancer	0.00248	0.0548	CcSEcCtD
Canagliflozin—ALB—gall bladder—colon cancer	0.0024	0.036	CbGeAlD
Canagliflozin—Dapagliflozin—ABCB1—colon cancer	0.00224	1	CrCbGaD
Canagliflozin—UGT2B4—liver—colon cancer	0.00223	0.0335	CbGeAlD
Canagliflozin—UGT1A9—digestive system—colon cancer	0.00205	0.0307	CbGeAlD
Canagliflozin—UGT1A9—liver—colon cancer	0.00152	0.0229	CbGeAlD
Canagliflozin—UGT2B4—Metapathway biotransformation—CHST4—colon cancer	0.00149	0.0967	CbGpPWpGaD
Canagliflozin—Sunburn—Methotrexate—colon cancer	0.00127	0.028	CcSEcCtD
Canagliflozin—Rash macular—Capecitabine—colon cancer	0.00125	0.0277	CcSEcCtD
Canagliflozin—Serum creatinine increased—Irinotecan—colon cancer	0.00125	0.0276	CcSEcCtD
Canagliflozin—Prurigo—Capecitabine—colon cancer	0.00111	0.0246	CcSEcCtD
Canagliflozin—ABCC2—renal system—colon cancer	0.00108	0.0162	CbGeAlD
Canagliflozin—ORM1—bone marrow—colon cancer	0.000992	0.0149	CbGeAlD
Canagliflozin—ABCC2—digestive system—colon cancer	0.000884	0.0133	CbGeAlD
Canagliflozin—ABCB1—blood vessel—colon cancer	0.000859	0.0129	CbGeAlD
Canagliflozin—Serum creatinine increased—Capecitabine—colon cancer	0.000835	0.0185	CcSEcCtD
Canagliflozin—ORM1—liver—colon cancer	0.000802	0.012	CbGeAlD
Canagliflozin—ABCC2—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000772	0.05	CbGpPWpGaD
Canagliflozin—Urine output increased—Vincristine—colon cancer	0.000713	0.0158	CcSEcCtD
Canagliflozin—ALB—liver—colon cancer	0.000703	0.0105	CbGeAlD
Canagliflozin—UGT2B4—Metapathway biotransformation—CHST5—colon cancer	0.000685	0.0444	CbGpPWpGaD
Canagliflozin—Rash erythematous—Capecitabine—colon cancer	0.000671	0.0148	CcSEcCtD
Canagliflozin—Rash maculo-papular—Fluorouracil—colon cancer	0.000668	0.0148	CcSEcCtD
Canagliflozin—ABCC2—liver—colon cancer	0.000659	0.00988	CbGeAlD
Canagliflozin—Multiple fractures—Methotrexate—colon cancer	0.000658	0.0146	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—colon cancer	0.000658	0.0146	CcSEcCtD
Canagliflozin—Polyuria—Vincristine—colon cancer	0.000652	0.0144	CcSEcCtD
Canagliflozin—SLC5A1—Carbohydrate metabolism—CHST5—colon cancer	0.000648	0.042	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—CHST5—colon cancer	0.000648	0.042	CbGpPWpGaD
Canagliflozin—ORM1—lymph node—colon cancer	0.000615	0.00922	CbGeAlD
Canagliflozin—Photosensitivity—Fluorouracil—colon cancer	0.000608	0.0134	CcSEcCtD
Canagliflozin—Renal failure acute—Irinotecan—colon cancer	0.000604	0.0134	CcSEcCtD
Canagliflozin—Nocturia—Capecitabine—colon cancer	0.000554	0.0123	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CHST4—colon cancer	0.000552	0.0358	CbGpPWpGaD
Canagliflozin—CYP3A4—renal system—colon cancer	0.000548	0.00822	CbGeAlD
Canagliflozin—ALB—lymph node—colon cancer	0.000539	0.00809	CbGeAlD
Canagliflozin—Dehydration—Vincristine—colon cancer	0.000532	0.0118	CcSEcCtD
Canagliflozin—Blood creatinine increased—Irinotecan—colon cancer	0.000522	0.0115	CcSEcCtD
Canagliflozin—Dehydration—Irinotecan—colon cancer	0.000518	0.0115	CcSEcCtD
Canagliflozin—ABCB1—embryo—colon cancer	0.000512	0.00768	CbGeAlD
Canagliflozin—Orthostatic hypotension—Irinotecan—colon cancer	0.000509	0.0113	CcSEcCtD
Canagliflozin—ABCC2—lymph node—colon cancer	0.000505	0.00758	CbGeAlD
Canagliflozin—Pancreatitis—Irinotecan—colon cancer	0.000472	0.0104	CcSEcCtD
Canagliflozin—Urine output increased—Capecitabine—colon cancer	0.000464	0.0103	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Vincristine—colon cancer	0.000451	0.00998	CcSEcCtD
Canagliflozin—CYP3A4—digestive system—colon cancer	0.000449	0.00674	CbGeAlD
Canagliflozin—Diabetes mellitus—Capecitabine—colon cancer	0.000429	0.00948	CcSEcCtD
Canagliflozin—Photosensitivity—Capecitabine—colon cancer	0.000425	0.0094	CcSEcCtD
Canagliflozin—Polyuria—Capecitabine—colon cancer	0.000425	0.0094	CcSEcCtD
Canagliflozin—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000422	0.0274	CbGpPWpGaD
Canagliflozin—Photosensitivity reaction—Fluorouracil—colon cancer	0.000421	0.00931	CcSEcCtD
Canagliflozin—ABCB1—epithelium—colon cancer	0.000418	0.00627	CbGeAlD
Canagliflozin—Renal failure acute—Capecitabine—colon cancer	0.000404	0.00894	CcSEcCtD
Canagliflozin—Urinary tract infection—Fluorouracil—colon cancer	0.0004	0.00884	CcSEcCtD
Canagliflozin—Thirst—Capecitabine—colon cancer	0.000392	0.00867	CcSEcCtD
Canagliflozin—Urinary tract disorder—Vincristine—colon cancer	0.000391	0.00865	CcSEcCtD
Canagliflozin—Urethral disorder—Vincristine—colon cancer	0.000388	0.00858	CcSEcCtD
Canagliflozin—ABCB1—renal system—colon cancer	0.000388	0.00582	CbGeAlD
Canagliflozin—Cystitis noninfective—Methotrexate—colon cancer	0.000374	0.00826	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—colon cancer	0.000369	0.00817	CcSEcCtD
Canagliflozin—UGT1A9—Irinotecan Pathway—APC—colon cancer	0.000364	0.0236	CbGpPWpGaD
Canagliflozin—Vaginal infection—Methotrexate—colon cancer	0.000361	0.00799	CcSEcCtD
Canagliflozin—Angiopathy—Vincristine—colon cancer	0.000359	0.00794	CcSEcCtD
Canagliflozin—ABCC2—Irinotecan Pathway—APC—colon cancer	0.000355	0.023	CbGpPWpGaD
Canagliflozin—Angiopathy—Irinotecan—colon cancer	0.00035	0.00774	CcSEcCtD
Canagliflozin—Blood creatinine increased—Capecitabine—colon cancer	0.000349	0.00773	CcSEcCtD
Canagliflozin—Dehydration—Capecitabine—colon cancer	0.000347	0.00767	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—colon cancer	0.000346	0.00765	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—colon cancer	0.000346	0.00765	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Capecitabine—colon cancer	0.000341	0.00753	CcSEcCtD
Canagliflozin—Breast disorder—Capecitabine—colon cancer	0.000337	0.00745	CcSEcCtD
Canagliflozin—CYP3A4—liver—colon cancer	0.000335	0.00502	CbGeAlD
Canagliflozin—ABCB1—lymphoid tissue—colon cancer	0.000322	0.00483	CbGeAlD
Canagliflozin—Erythema—Fluorouracil—colon cancer	0.000321	0.00711	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—colon cancer	0.000319	0.00706	CcSEcCtD
Canagliflozin—ABCB1—digestive system—colon cancer	0.000318	0.00477	CbGeAlD
Canagliflozin—Polyuria—Methotrexate—colon cancer	0.000316	0.00699	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—colon cancer	0.000316	0.00699	CcSEcCtD
Canagliflozin—Syncope—Irinotecan—colon cancer	0.000301	0.00666	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—colon cancer	0.000301	0.00665	CcSEcCtD
Canagliflozin—Convulsion—Vincristine—colon cancer	0.000299	0.0066	CcSEcCtD
Canagliflozin—Loss of consciousness—Irinotecan—colon cancer	0.000295	0.00652	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Capecitabine—colon cancer	0.000294	0.00651	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—colon cancer	0.000293	0.0044	CbGeAlD
Canagliflozin—ABCB1—vagina—colon cancer	0.000281	0.00421	CbGeAlD
Canagliflozin—Infection—Vincristine—colon cancer	0.000279	0.00618	CcSEcCtD
Canagliflozin—Urinary tract infection—Capecitabine—colon cancer	0.000279	0.00618	CcSEcCtD
Canagliflozin—Convulsion—Fluorouracil—colon cancer	0.000278	0.00616	CcSEcCtD
Canagliflozin—Nervous system disorder—Vincristine—colon cancer	0.000276	0.0061	CcSEcCtD
Canagliflozin—Infection—Irinotecan—colon cancer	0.000272	0.00602	CcSEcCtD
Canagliflozin—Shock—Irinotecan—colon cancer	0.000269	0.00596	CcSEcCtD
Canagliflozin—Nervous system disorder—Irinotecan—colon cancer	0.000269	0.00594	CcSEcCtD
Canagliflozin—Hypotension—Vincristine—colon cancer	0.000263	0.00581	CcSEcCtD
Canagliflozin—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000261	0.0169	CbGpPWpGaD
Canagliflozin—Infection—Fluorouracil—colon cancer	0.000261	0.00576	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—colon cancer	0.000257	0.00569	CcSEcCtD
Canagliflozin—Hypotension—Irinotecan—colon cancer	0.000256	0.00566	CcSEcCtD
Canagliflozin—Urinary tract disorder—Capecitabine—colon cancer	0.000255	0.00564	CcSEcCtD
Canagliflozin—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000255	0.0165	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CA7—colon cancer	0.000254	0.0165	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CA7—colon cancer	0.000254	0.0165	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—CHST5—colon cancer	0.000254	0.0164	CbGpPWpGaD
Canagliflozin—Urethral disorder—Capecitabine—colon cancer	0.000253	0.00559	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—colon cancer	0.000251	0.00555	CcSEcCtD
Canagliflozin—Hypotension—Fluorouracil—colon cancer	0.000245	0.00542	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vincristine—colon cancer	0.000243	0.00537	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000242	0.0157	CbGpPWpGaD
Canagliflozin—Fatigue—Vincristine—colon cancer	0.000242	0.00536	CcSEcCtD
Canagliflozin—Constipation—Vincristine—colon cancer	0.00024	0.00532	CcSEcCtD
Canagliflozin—ABCB1—liver—colon cancer	0.000237	0.00355	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Irinotecan—colon cancer	0.000236	0.00523	CcSEcCtD
Canagliflozin—Fatigue—Irinotecan—colon cancer	0.000236	0.00522	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—colon cancer	0.000235	0.0052	CcSEcCtD
Canagliflozin—Constipation—Irinotecan—colon cancer	0.000234	0.00518	CcSEcCtD
Canagliflozin—Angiopathy—Capecitabine—colon cancer	0.000234	0.00518	CcSEcCtD
Canagliflozin—ABCC2—ABC-family proteins mediated transport—ABCB1—colon cancer	0.000232	0.015	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Vincristine—colon cancer	0.00023	0.00509	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000226	0.00501	CcSEcCtD
Canagliflozin—Malnutrition—Capecitabine—colon cancer	0.000225	0.00497	CcSEcCtD
Canagliflozin—Erythema—Capecitabine—colon cancer	0.000225	0.00497	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Irinotecan—colon cancer	0.000224	0.00495	CcSEcCtD
Canagliflozin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000223	0.0145	CbGpPWpGaD
Canagliflozin—Abdominal pain—Vincristine—colon cancer	0.000222	0.00492	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—colon cancer	0.000219	0.00484	CcSEcCtD
Canagliflozin—Abdominal pain—Irinotecan—colon cancer	0.000216	0.00479	CcSEcCtD
Canagliflozin—Urticaria—Fluorouracil—colon cancer	0.000208	0.00461	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—colon cancer	0.000207	0.00458	CcSEcCtD
Canagliflozin—Hypersensitivity—Irinotecan—colon cancer	0.000202	0.00446	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—colon cancer	0.000202	0.00446	CcSEcCtD
Canagliflozin—Syncope—Capecitabine—colon cancer	0.000201	0.00446	CcSEcCtD
Canagliflozin—Loss of consciousness—Capecitabine—colon cancer	0.000197	0.00437	CcSEcCtD
Canagliflozin—Asthenia—Irinotecan—colon cancer	0.000196	0.00435	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CA7—colon cancer	0.000196	0.0127	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Fluorouracil—colon cancer	0.000193	0.00427	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00019	0.0042	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—colon cancer	0.00019	0.0042	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—colon cancer	0.000188	0.00416	CcSEcCtD
Canagliflozin—Dry mouth—Capecitabine—colon cancer	0.000187	0.00414	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—colon cancer	0.000186	0.00411	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—colon cancer	0.000186	0.00411	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000185	0.012	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CHST5—colon cancer	0.000184	0.0119	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—LGR5—colon cancer	0.000184	0.0119	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CHST5—colon cancer	0.000184	0.0119	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—LGR5—colon cancer	0.000184	0.0119	CbGpPWpGaD
Canagliflozin—Infection—Capecitabine—colon cancer	0.000182	0.00403	CcSEcCtD
Canagliflozin—ABCB1—lymph node—colon cancer	0.000182	0.00272	CbGeAlD
Canagliflozin—Dizziness—Irinotecan—colon cancer	0.000181	0.00401	CcSEcCtD
Canagliflozin—Shock—Capecitabine—colon cancer	0.00018	0.00399	CcSEcCtD
Canagliflozin—Nervous system disorder—Capecitabine—colon cancer	0.00018	0.00398	CcSEcCtD
Canagliflozin—Skin disorder—Capecitabine—colon cancer	0.000178	0.00394	CcSEcCtD
Canagliflozin—Rash—Vincristine—colon cancer	0.000177	0.00392	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—colon cancer	0.000177	0.00392	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—colon cancer	0.000174	0.00385	CcSEcCtD
Canagliflozin—Dizziness—Fluorouracil—colon cancer	0.000173	0.00384	CcSEcCtD
Canagliflozin—Rash—Irinotecan—colon cancer	0.000173	0.00382	CcSEcCtD
Canagliflozin—Dermatitis—Irinotecan—colon cancer	0.000173	0.00382	CcSEcCtD
Canagliflozin—Hypotension—Capecitabine—colon cancer	0.000171	0.00379	CcSEcCtD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.00017	0.011	CbGpPWpGaD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000169	0.0109	CbGpPWpGaD
Canagliflozin—Erythema—Methotrexate—colon cancer	0.000167	0.0037	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—colon cancer	0.000167	0.0037	CcSEcCtD
Canagliflozin—Nausea—Vincristine—colon cancer	0.000167	0.00369	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—colon cancer	0.000165	0.00366	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—colon cancer	0.000165	0.00366	CcSEcCtD
Canagliflozin—Nausea—Irinotecan—colon cancer	0.000163	0.0036	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Capecitabine—colon cancer	0.000158	0.0035	CcSEcCtD
Canagliflozin—Fatigue—Capecitabine—colon cancer	0.000158	0.0035	CcSEcCtD
Canagliflozin—Constipation—Capecitabine—colon cancer	0.000157	0.00347	CcSEcCtD
Canagliflozin—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000156	0.0101	CbGpPWpGaD
Canagliflozin—Nausea—Fluorouracil—colon cancer	0.000156	0.00345	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—ODC1—colon cancer	0.000154	0.00997	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CHST5—colon cancer	0.000154	0.00997	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CHST5—colon cancer	0.000154	0.00997	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ODC1—colon cancer	0.000154	0.00997	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CCND1—colon cancer	0.000152	0.00987	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Capecitabine—colon cancer	0.00015	0.00332	CcSEcCtD
Canagliflozin—Urticaria—Capecitabine—colon cancer	0.000146	0.00322	CcSEcCtD
Canagliflozin—Abdominal pain—Capecitabine—colon cancer	0.000145	0.00321	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—colon cancer	0.000145	0.0032	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000141	0.00313	CcSEcCtD
Canagliflozin—Infection—Methotrexate—colon cancer	0.000136	0.003	CcSEcCtD
Canagliflozin—Hypersensitivity—Capecitabine—colon cancer	0.000135	0.00299	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—colon cancer	0.000134	0.00296	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—colon cancer	0.000133	0.00293	CcSEcCtD
Canagliflozin—SLC5A2—Disease—AXIN2—colon cancer	0.000132	0.00855	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AXIN2—colon cancer	0.000132	0.00855	CbGpPWpGaD
Canagliflozin—Asthenia—Capecitabine—colon cancer	0.000132	0.00291	CcSEcCtD
Canagliflozin—Pruritus—Capecitabine—colon cancer	0.00013	0.00287	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—colon cancer	0.000127	0.00282	CcSEcCtD
Canagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000122	0.00792	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—colon cancer	0.000122	0.00792	CbGpPWpGaD
Canagliflozin—Dizziness—Capecitabine—colon cancer	0.000121	0.00268	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—ODC1—colon cancer	0.000119	0.0077	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CHST5—colon cancer	0.000119	0.0077	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Methotrexate—colon cancer	0.000118	0.00261	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—colon cancer	0.000118	0.0026	CcSEcCtD
Canagliflozin—Rash—Capecitabine—colon cancer	0.000116	0.00256	CcSEcCtD
Canagliflozin—Dermatitis—Capecitabine—colon cancer	0.000115	0.00255	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—colon cancer	0.000112	0.00247	CcSEcCtD
Canagliflozin—Nausea—Capecitabine—colon cancer	0.000109	0.00241	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—colon cancer	0.000108	0.0024	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—colon cancer	0.000108	0.00239	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000107	0.00696	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—TGFB1—colon cancer	0.000107	0.00695	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—TGFB1—colon cancer	0.000107	0.00695	CbGpPWpGaD
Canagliflozin—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000103	0.00667	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Methotrexate—colon cancer	0.000101	0.00222	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—colon cancer	9.79e-05	0.00217	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—colon cancer	9.65e-05	0.00214	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—colon cancer	9.02e-05	0.002	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	8.88e-05	0.00575	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ABCB1—colon cancer	8.68e-05	0.00562	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ABCB1—colon cancer	8.68e-05	0.00562	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	8.64e-05	0.0056	CbGpPWpGaD
Canagliflozin—Rash—Methotrexate—colon cancer	8.6e-05	0.0019	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—colon cancer	8.59e-05	0.0019	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—colon cancer	8.1e-05	0.00179	CcSEcCtD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	8e-05	0.00518	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	7.93e-05	0.00514	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	7.72e-05	0.005	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	7.57e-05	0.0049	CbGpPWpGaD
Canagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	7.37e-05	0.00478	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA7—colon cancer	7.26e-05	0.0047	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	7.17e-05	0.00464	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	7.02e-05	0.00455	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—PPARG—colon cancer	6.76e-05	0.00438	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	6.61e-05	0.00429	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	5.46e-05	0.00353	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	4.89e-05	0.00317	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	4.59e-05	0.00298	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	4.56e-05	0.00295	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—EP300—colon cancer	4.42e-05	0.00286	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ODC1—colon cancer	4.4e-05	0.00285	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CHST5—colon cancer	4.4e-05	0.00285	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	4.33e-05	0.0028	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ABCB1—colon cancer	4.07e-05	0.00263	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ABCB1—colon cancer	4.07e-05	0.00263	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TYMS—colon cancer	3.99e-05	0.00259	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TYMS—colon cancer	3.99e-05	0.00259	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—FGFR3—colon cancer	3.81e-05	0.00247	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—FGFR3—colon cancer	3.81e-05	0.00247	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA7—colon cancer	3.8e-05	0.00246	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	3.67e-05	0.00238	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APC—colon cancer	3.5e-05	0.00227	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APC—colon cancer	3.5e-05	0.00227	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	3.38e-05	0.00219	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA7—colon cancer	3.33e-05	0.00216	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	3.33e-05	0.00216	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—BRAF—colon cancer	3.29e-05	0.00213	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—BRAF—colon cancer	3.29e-05	0.00213	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ABCB1—colon cancer	3.14e-05	0.00203	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TYMS—colon cancer	3.08e-05	0.002	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—colon cancer	3.06e-05	0.00199	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	3.05e-05	0.00198	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—colon cancer	2.99e-05	0.00194	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	2.98e-05	0.00193	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP3—colon cancer	2.95e-05	0.00191	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	2.91e-05	0.00189	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	2.89e-05	0.00187	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—colon cancer	2.83e-05	0.00183	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—colon cancer	2.83e-05	0.00183	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—colon cancer	2.83e-05	0.00183	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	2.81e-05	0.00182	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	2.71e-05	0.00176	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	2.69e-05	0.00175	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—colon cancer	2.66e-05	0.00172	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—colon cancer	2.66e-05	0.00172	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—colon cancer	2.6e-05	0.00168	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—colon cancer	2.5e-05	0.00162	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—colon cancer	2.49e-05	0.00162	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	2.47e-05	0.0016	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.42e-05	0.00157	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CTNNB1—colon cancer	2.38e-05	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CTNNB1—colon cancer	2.38e-05	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1A—colon cancer	2.32e-05	0.0015	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1A—colon cancer	2.32e-05	0.0015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CHST5—colon cancer	2.3e-05	0.00149	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ODC1—colon cancer	2.3e-05	0.00149	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—colon cancer	2.3e-05	0.00149	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—colon cancer	2.23e-05	0.00144	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—colon cancer	2.23e-05	0.00144	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EP300—colon cancer	2.21e-05	0.00143	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EP300—colon cancer	2.21e-05	0.00143	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—colon cancer	2.18e-05	0.00142	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SRC—colon cancer	2.15e-05	0.00139	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SRC—colon cancer	2.15e-05	0.00139	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRAS—colon cancer	2.07e-05	0.00134	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRAS—colon cancer	2.07e-05	0.00134	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.07e-05	0.00134	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA7—colon cancer	2.05e-05	0.00133	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ODC1—colon cancer	2.02e-05	0.00131	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CHST5—colon cancer	2.02e-05	0.00131	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—colon cancer	1.93e-05	0.00125	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—colon cancer	1.93e-05	0.00125	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—colon cancer	1.92e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—colon cancer	1.92e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—colon cancer	1.88e-05	0.00122	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—colon cancer	1.88e-05	0.00122	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—EP300—colon cancer	1.85e-05	0.0012	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—EP300—colon cancer	1.85e-05	0.0012	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	1.84e-05	0.0012	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.81e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—colon cancer	1.78e-05	0.00115	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—colon cancer	1.78e-05	0.00115	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—colon cancer	1.72e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—colon cancer	1.63e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—colon cancer	1.63e-05	0.00106	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	1.57e-05	0.00102	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—colon cancer	1.51e-05	0.00098	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—colon cancer	1.51e-05	0.00098	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.46e-05	0.000943	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—colon cancer	1.43e-05	0.000926	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.43e-05	0.000925	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.42e-05	0.000918	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.4e-05	0.000909	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.37e-05	0.000888	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—colon cancer	1.37e-05	0.000887	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—colon cancer	1.37e-05	0.000887	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—colon cancer	1.34e-05	0.000865	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—colon cancer	1.34e-05	0.000865	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.3e-05	0.000845	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	1.3e-05	0.000841	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	1.29e-05	0.000835	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.27e-05	0.000822	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.25e-05	0.000813	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CHST5—colon cancer	1.24e-05	0.000805	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ODC1—colon cancer	1.24e-05	0.000805	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.24e-05	0.000801	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.19e-05	0.000769	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—colon cancer	1.16e-05	0.000753	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.15e-05	0.000746	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—colon cancer	1.14e-05	0.000739	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.14e-05	0.000737	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.13e-05	0.000735	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—colon cancer	1.12e-05	0.000725	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—colon cancer	1.12e-05	0.000725	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.11e-05	0.00072	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—colon cancer	1.06e-05	0.000685	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.05e-05	0.000681	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	9.8e-06	0.000635	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	9.65e-06	0.000625	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.5e-06	0.000616	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	9.34e-06	0.000605	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.78e-06	0.000569	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—colon cancer	8.63e-06	0.000559	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—colon cancer	8.08e-06	0.000524	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	8.01e-06	0.000519	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	7.88e-06	0.000511	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.48e-06	0.000484	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—colon cancer	6.83e-06	0.000442	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—colon cancer	6.64e-06	0.00043	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—colon cancer	6.47e-06	0.000419	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—colon cancer	6.39e-06	0.000414	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—colon cancer	6.36e-06	0.000412	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.22e-06	0.000403	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—colon cancer	6.08e-06	0.000394	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—colon cancer	5.97e-06	0.000387	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—colon cancer	5.94e-06	0.000385	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—colon cancer	5.5e-06	0.000356	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—colon cancer	5.29e-06	0.000343	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—colon cancer	5.23e-06	0.000339	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—colon cancer	5.05e-06	0.000327	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—colon cancer	4.89e-06	0.000317	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—colon cancer	4.67e-06	0.000303	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.6e-06	0.000298	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—colon cancer	4.23e-06	0.000274	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—colon cancer	4.13e-06	0.000267	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—colon cancer	3.91e-06	0.000253	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—colon cancer	3.71e-06	0.00024	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—colon cancer	3.33e-06	0.000216	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—colon cancer	3.28e-06	0.000213	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—colon cancer	3.22e-06	0.000209	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—colon cancer	3.2e-06	0.000207	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—colon cancer	2.92e-06	0.000189	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—colon cancer	2.77e-06	0.000179	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—colon cancer	2.43e-06	0.000157	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—colon cancer	2.28e-06	0.000148	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—colon cancer	2.05e-06	0.000133	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—colon cancer	1.8e-06	0.000116	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—colon cancer	1.79e-06	0.000116	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—colon cancer	1.67e-06	0.000108	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—colon cancer	1.49e-06	9.68e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—colon cancer	1.47e-06	9.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—colon cancer	1.11e-06	7.16e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—colon cancer	9.03e-07	5.85e-05	CbGpPWpGaD
